United States: Left To Their Own Devices: Administration, FDA Turn To Medical Device Innovation

Ethan Jorgensen-Earp is a Public Affairs Advisor in the Washington D.C. office

HIGHLIGHTS:

  • Masked by the recent high-profile drug pricing debate has been the Trump Administration's discussions about the development, approval and reimbursement of medical devices. Recent comments by Administration leaders, as well as recent regulatory actions, indicate that the landscape may be changing for the better.
  • Even with steady improvements in terms of speed of review and decision times, the U.S. Food and Drug Administration (FDA) has signaled the need for new thinking around device approvals. As medical technology becomes more complex, the FDA must anticipate and adapt existing approval frameworks to match the technologies that patients need while also utilizing every available resource, including those outside the agency, to speed effective devices to market.
  • The Administration also is focusing on the reimbursement of devices, including increased coordination efforts with the Centers for Medicare & Medicaid Services (CMS)

It has been almost impossible to exist in Washington, D.C., during the past several months without encountering the drug pricing debate. From fiery tweets to Rose Garden announcements and speeches, President Donald Trump, along with Secretary of Health and Human Services (HHS) Alex Azar and other Trump Administration officials, have adopted the issue of reduced drug prices as a major domestic policy priority. Masked by this and other discussions about drug development and marketing, however, has been the discussion about the development, approval and reimbursement of medical devices. Recent comments by Administration leaders, as well as recent regulatory actions, indicate that the landscape may be changing for the better.

Background

Since 1976, when the U.S. Food and Drug Administration (FDA) clarified its legal authority to regulate devices, the device approval process at the FDA has had mixed reviews. For devices that are important for sustaining life and function or those that are associated with potentially high risk of injury or illness, also known as Class III devices, the FDA's Center for Devices and Radiological Health (CDRH) relies on the Pre-Market Approval (PMA) pathway, which requires sponsors to submit substantial data and evidence showing that the devices are safe and effective. For Class I and II devices, which present fewer health risks, application reviews can be accelerated. Many of these devices, which range from wound dressings and some pregnancy tests to powered wheelchairs, are able to be approved through a process colloquially known as "510(k),"1 which requires manufacturers to prove that their device is substantially equivalent to a previously marketed device that does not require a PMA.

In terms of actual speed of review and decision times, FDA has improved steadily, with PMA decisions typically taking more than 200 days (down from more than 400 days in 2008) and 510(k) decisions coming in fewer than 150 to 200 days and decreasing.2 FDA, however, is still feeling pressure to be more responsive, and, through congressional authority, has accelerated consideration of innovative devices.3 For instance, sponsors submitting device applications, including 510(k) applications, have several avenues for accelerated consideration of "breakthrough" devices that treat unmet medical need. However, even with these existing programs, the FDA has signaled the need for new thinking around device approvals. As medical technology becomes more complex, the FDA must anticipate and adapt existing approval frameworks to match the technologies that patients need while also utilizing every available resource, including those outside the agency, to speed effective devices to market.

In September 2018, for instance, FDA launched the Quality in 510(k) "Quik" Review Program, which uses software to format an application for more efficient review.4 FDA has also recently released final guidance that helps clarify when developers of next generation sequencing (NGS) and other genetic and genomic tests may rely on FDA-approved public databases to provide information for determining the accuracy of these tests, helping to speed diagnostic technology to the market that could help many patients, including those with difficult-to-diagnose rare diseases. The expanded use of FDA resources, such as public databases, builds off of decades-long efforts by the agency to increase its ability to quickly clear devices, especially those that are lower risk, for use by patients. For instance, FDA was granted new authority in the late 1990s and early 2000sto approve third parties to respectively conduct the initial review of 510(k) applications and perform medical device facility inspections to ensure manufacturing quality control for Class II and III devices.56 However, given that only a handful of third-party reviewers have officially been registered and that the program is generally underutilized, FDA recently released new guidance in an attempt to revamp the program to help the agency meet the constant demand for safe and effective device technology.

Renewed Focus on Reimbursement

Although these changes have and will likely help reduce review times, approval and actual reimbursement of new devices are two very different things. To help bridge this gap, greater coordination and cooperation from other agencies will be needed to ensure device uptake by providers, and Administration and public priorities are shifting to a focus on reimbursement. In late September, Joe Grogan, Associate Director of Health Programs at the White House's Office of Management and Budget (OMB), said publicly that the Administration is taking a renewed focus on reimbursement of devices in addition to their approval as safe and effective by the FDA.7 Interest in this issue from some of the Administration's top officials follows longtime commentary from many in the device world that coverage of new devices can be extremely slow even if their review and approval was accelerated by FDA.

The lag between FDA approval and the coverage of devices by payers such as Medicare and private insurers is not a new concern, and is driven in large part by the amount of evidence required by a payer to justify a device's use in a population that goes above and beyond that required by FDA to show safety and efficacy. Coverage delays and inadequate payment may also be disproportionately felt by new and innovative technologies that do not fit within an existing payment paradigm, where value may not be able to be adequately measured and translated into reimbursement compared with pre-existing technology. Indeed, in many cases, the Centers for Medicare & Medicaid Services (CMS) and private insurers make different decisions regarding the coverage of devices, making it difficult for manufacturers to see a path forward for new technologies. Thus, increased FDA and CMS coordination at the very least offers a chance to shift this paradigm.

Increased Collaboration Efforts

In general, the FDA and CMS have a blanket agreement to collaborate on ways to enhance information sharing related to evaluating new medical products.8 Shortly after this agreement was developed, FDA and CMS in September 2010 announced the launch of a pilot program that would establish a system for "parallel review" of certain medical device applications, including those at the investigational level, by both FDA and CMS in order to shorten the time it takes for the device to be FDA-approved and also covered under an existing Medicare Part A or B benefit category.9 Despite HHS' intention to keep the program going indefinitely, only two devices have actually been approved through this program and received a national coverage determination (NCD) from CMS, including an NGS test that also benefited from FDA's breakthrough devices program.10 Although largely ineffective, the parallel review program can serve as a model for new pilot programs to help shepherd new technologies through the coverage maze.

It's also important for the FDA to continue to have conversations and agreements with other agencies, not only for payment but also to ensure that new, innovative devices are safe for patients from a data and security perspective. For instance, unlike traditional medicines, some medical devices, now labeled by FDA as "Tier 1" devices, and their related software face the same cybersecurity threats that confront many other non-medical sectors.11 Indeed, the U.S. Department of Homeland Security (DHS) and FDA very recently established a memorandum of understanding that formalized the relationship between the two agencies related to cybersecurity, in which DHS' National Protection and Programs Directorate would lead device-related cybersecurity policy and FDA would provide any technical assistance necessary from the device regulation and approval side. The formalizing of this relationship, which has existed informally for years, may seem small, but it indicates the extent to which agencies must cooperate in order to bring new and innovative technologies to the nation's sickest patients.

Furthermore, FDA will likely attempt to engage in conversations with CMS' innovation center, the Center for Medicare & Medicaid Innovation (CMMI), on accelerated coverage of devices. Although lawmakers' opinions on CMMI vary, Director Adam Boehler, a longtime private-sector healthcare executive, has expressed interest in looking into numerous healthcare innovation issues, from value-based care models to artificial intelligence, which could include new payment models around the coverage of innovative or breakthrough devices. Indeed, the idea of CMS focusing on this issue was bolstered with the Oct. 17, 2018, announcement of a new proposed rule, set for publication in March 2019, that would address coverage of "breakthrough technologies [that] have the potential to improve patient health outcomes."12 CMMI, in concert with existing CMS entities such as its Council for Technology & Innovation,13 could have a significant impact on the coverage of new and lifesaving devices, provided that each respective agency securely shares data and information about these technologies to the fullest extent possible.

Without new mechanisms for the secure sharing of information between agencies, the development of new device technologies promised in discussions around the 21st Century Cures Act and recent major Trump Administration announcements may simply be a mirage. 

Footnotes

1 510(k) refers to Section 510(k) of the Federal Food, Drug, and Cosmetic Act that outlines in statute this particular approval process.

2 U.S. Food and Drug Administration. Agenda for Quarterly Meeting on MDUFA IV (FY 2018-2022) Performance. Sept. 11, 2018.

3 U.S. Food and Drug Administration. 510(k) Submission Process. Accessed: Oct. 18, 2018.

4 U.S. Food and Drug Administration. 510(k) Program Pilots. Accessed: Oct. 18, 2018 .

5 21 U.S.C. §360m.

6 21 U.S.C. §374(g).

7 MM Stein. OMB Health Chief: Changes to How CMS Treats Medical Devices Coming. Inside CMS. Sept. 9, 2018:21(39).

8 75 Federal Register 48699.

9 76 Federal Register 62808.

10 M. Mezher. FDA, CMS: Second Parallel Review Decision Ever for NGS Test. Regulatory Focus. Dec. 1, 2017.

11 U.S. Food and Drug Administration. Content of Premarket Submissions for Management of Cybersecurity in Medical Devices: Draft Guidance for Industry and Food and Drug Administration Staff. Oct. 18, 2018.

12 Centers for Medicare & Medicaid Services. CMS-3372-P. RIN: 0938-AT88.

13 42 U.S.C. §1395ee(b).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
 
In association with
Related Topics
 
Similar Articles
Relevancy Powered by MondaqAI
Finnegan, Henderson, Farabow, Garrett & Dunner, LLP
Related Articles
 
Related Video
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions